To demonstrate that our optimal combinations can also be applied to imatinib-resistant cells, we selected 49 drug combinations and tested them in the SUP-B15 cell line and ALL patient cells with and without the BCR-ABL translocation (Table S5). This evidence concerns the gene BCR and acute lymphoblastic leukemia.